Debra J Zack

Summary

Affiliation: Amgen Inc
Country: USA

Publications

  1. ncbi Summary of worldwide pediatric malignancies reported after exposure to etanercept
    Peter McCroskery
    Amgen Inc, Thousand Oaks, CA, Seattle WA, and South San Francisco, CA, USA
    Pediatr Rheumatol Online J 8:18. 2010
  2. ncbi A randomized, double-blind study of AMG 108 (a fully human monoclonal antibody to IL-1R1) in patients with osteoarthritis of the knee
    Stanley B Cohen
    Rheumatology, Metroplex Clinical Research Center, 8144 Walnut Hill Lane, Dallas, TX 75231, USA
    Arthritis Res Ther 13:R125. 2011
  3. ncbi RANKL inhibition by osteoprotegerin prevents bone loss without affecting local or systemic inflammation parameters in two rat arthritis models: comparison with anti-TNFalpha or anti-IL-1 therapies
    Marina Stolina
    Department of Metabolic Disorders, Amgen Inc, One Amgen Center Drive, Thousand Oaks, CA 91320, USA
    Arthritis Res Ther 11:R187. 2009
  4. ncbi A phase 2 randomized, double-blind study of AMG 108, a fully human monoclonal antibody to IL-1R, in patients with rheumatoid arthritis
    Mario H Cardiel
    Centro de Investigacion Clinica de Morelia, Morelia, Virrey de Mendoza 1998 Int, 522 Col Félix Ireta, Mich 58070, Mexico
    Arthritis Res Ther 12:R192. 2010
  5. ncbi RANKL inhibition: from mice to men (and women)
    Marina Stolina
    Department of Metabolic Disorders, Amgen Inc, Thousand Oaks, CA, USA
    Adv Exp Med Biol 602:143-50. 2007
  6. ncbi Continuous RANKL inhibition in osteoprotegerin transgenic mice and rats suppresses bone resorption without impairing lymphorganogenesis or functional immune responses
    Marina Stolina
    Department of Metabolic Disorders, Amgen Inc, Thousand Oaks, CA 91320, USA
    J Immunol 179:7497-505. 2007
  7. ncbi The evolving systemic and local biomarker milieu at different stages of disease progression in rat collagen-induced arthritis
    Marina Stolina
    Department of Metabolic Disorders, Amgen Inc, One Amgen Center Drive, Thousand Oaks, CA 91320 1799, USA
    Biomarkers 13:692-712. 2008
  8. ncbi Analysis of the kinetics of osteoclastogenesis in arthritic rats
    Georg Schett
    Amgen, Inc, Thousand Oaks, California 91320, USA
    Arthritis Rheum 52:3192-201. 2005
  9. ncbi Additive bone-protective effects of anabolic treatment when used in conjunction with RANKL and tumor necrosis factor inhibition in two rat arthritis models
    Georg Schett
    Amgen Inc, Thousand Oaks, California, and Medical University of Vienna, Vienna, Austria
    Arthritis Rheum 52:1604-11. 2005

Collaborators

  • Marina Stolina
  • B Bolon
  • Georg Schett
  • Lorraine A Fitzpatrick
  • William C Dougall
  • Daniel J Lovell
  • Stanley B Cohen
  • Francis X Burch
  • Liyun Ni
  • Mario H Cardiel
  • Peter McCroskery
  • Deborah Burstein
  • John P Donohue
  • Susanna Proudman
  • Yu Nien Sun
  • Christopher Banfield
  • Alan J Kivitz
  • Michael S Vincent
  • Scott Stryker
  • Janusz E Badurski
  • Nataliya Chernyukhin
  • Sarka Forejtova
  • Ellen McCroskery
  • Carol A Wallace
  • Angelika Jahreis
  • Paul P Tak
  • Tarundeep Kakkar
  • Terry Bevirt
  • William Bensen
  • Consuelo Blosch

Detail Information

Publications9

  1. ncbi Summary of worldwide pediatric malignancies reported after exposure to etanercept
    Peter McCroskery
    Amgen Inc, Thousand Oaks, CA, Seattle WA, and South San Francisco, CA, USA
    Pediatr Rheumatol Online J 8:18. 2010
    ..We examined the worldwide experience of etanercept use in pediatric patients and the occurrence of malignancies as reported from clinical trials, registry studies, post-marketing surveillance, and published scientific literature...
  2. ncbi A randomized, double-blind study of AMG 108 (a fully human monoclonal antibody to IL-1R1) in patients with osteoarthritis of the knee
    Stanley B Cohen
    Rheumatology, Metroplex Clinical Research Center, 8144 Walnut Hill Lane, Dallas, TX 75231, USA
    Arthritis Res Ther 13:R125. 2011
    ..The purpose of this two-part study was to evaluate the safety and pharmacokinetics (PK; Part A) and clinical effect (Part B) of AMG 108 in a double-blind, placebo-controlled, multiple-dose study in patients with OA of the knee...
  3. ncbi RANKL inhibition by osteoprotegerin prevents bone loss without affecting local or systemic inflammation parameters in two rat arthritis models: comparison with anti-TNFalpha or anti-IL-1 therapies
    Marina Stolina
    Department of Metabolic Disorders, Amgen Inc, One Amgen Center Drive, Thousand Oaks, CA 91320, USA
    Arthritis Res Ther 11:R187. 2009
    ..RANKL inhibition consistently prevents bone loss in both models without reducing joint inflammation. Effects of these therapies on systemic markers of bone turnover and inflammation have not been directly compared...
  4. ncbi A phase 2 randomized, double-blind study of AMG 108, a fully human monoclonal antibody to IL-1R, in patients with rheumatoid arthritis
    Mario H Cardiel
    Centro de Investigacion Clinica de Morelia, Morelia, Virrey de Mendoza 1998 Int, 522 Col Félix Ireta, Mich 58070, Mexico
    Arthritis Res Ther 12:R192. 2010
    ....
  5. ncbi RANKL inhibition: from mice to men (and women)
    Marina Stolina
    Department of Metabolic Disorders, Amgen Inc, Thousand Oaks, CA, USA
    Adv Exp Med Biol 602:143-50. 2007
    ..In addition, in a subset of patients tested for immunological markers, there were no clinically meaningful differences in T, B, or NK cell numbers or in immunoglobulin levels across dose or treatment groups...
  6. ncbi Continuous RANKL inhibition in osteoprotegerin transgenic mice and rats suppresses bone resorption without impairing lymphorganogenesis or functional immune responses
    Marina Stolina
    Department of Metabolic Disorders, Amgen Inc, Thousand Oaks, CA 91320, USA
    J Immunol 179:7497-505. 2007
    ..In summary, prenatal RANKL inhibition did not impair lymph node development, nor did continuous life-long RANKL inhibition cause obvious changes in innate or humoral immune responses in mice or rats...
  7. ncbi The evolving systemic and local biomarker milieu at different stages of disease progression in rat collagen-induced arthritis
    Marina Stolina
    Department of Metabolic Disorders, Amgen Inc, One Amgen Center Drive, Thousand Oaks, CA 91320 1799, USA
    Biomarkers 13:692-712. 2008
    ..These data indicate that systemic and local events in inflammatory arthritis can be discrete processes, driven by multiple cellular and humoral mediators with distinct temporospatial profiles...
  8. ncbi Analysis of the kinetics of osteoclastogenesis in arthritic rats
    Georg Schett
    Amgen, Inc, Thousand Oaks, California 91320, USA
    Arthritis Rheum 52:3192-201. 2005
    ..These data indicate that anti-resorptive therapies may provide the most effective bone protection, when treatment is started soon after the onset of arthritis...
  9. ncbi Additive bone-protective effects of anabolic treatment when used in conjunction with RANKL and tumor necrosis factor inhibition in two rat arthritis models
    Georg Schett
    Amgen Inc, Thousand Oaks, California, and Medical University of Vienna, Vienna, Austria
    Arthritis Rheum 52:1604-11. 2005
    ..CONCLUSION: The bone-protective effects resulting from RANKL or TNF antagonism can be further improved by the addition of a bone anabolic agent...